McIntyre, Freedman & Flynn Investment Advisers’s ClearPoint Neuro CLPT Stock Holding History

McIntyre, Freedman & Flynn Investment Advisers’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$232K	Buy	+13,000	New	+$162K	0.14%	76

Other funds holding CLPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CFML

COMPASS FINANCIAL MANAGEMENT LLC Tampa, Florida $829M AUM

Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

PHS

Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return

FCM

FirstWave Capital Management Miami, Florida $227M AUM

McIntyre, Freedman & Flynn Investment Advisers's CLPT Position: Q2 2026 in Review

McIntyre, Freedman & Flynn Investment Advisers opened a new position in ClearPoint Neuro (CLPT) in Q2 2026: 13,000 shares worth $232K. The stake represents 0.14% of the portfolio and ranks #76 among its holdings.

69 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

McIntyre, Freedman & Flynn Investment Advisers held 13,000 shares of ClearPoint Neuro worth $232K as of Q2 2026.
ClearPoint Neuro was a new McIntyre, Freedman & Flynn Investment Advisers position in Q2 2026.
ClearPoint Neuro made up 0.14% of McIntyre, Freedman & Flynn Investment Advisers's portfolio in Q2 2026, its #76 holding.
69 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on McIntyre, Freedman & Flynn Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.